Your session is about to expire
← Back to Search
Substudy (Optional Cohort C) - Sotrovimab up to 3000 mg IV for Coronavirus
Study Summary
This trial is testing a new antibody drug to see if it is effective and safe for treating mild to moderate COVID-19 in non-hospitalized high-risk patients. There is also a safety substudy to assess the safety and tolerability of a single dose of the drug.
- Coronavirus
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For what reasons is VIR-7831 sotrovimab given to patients?
"A positive sarscov-2 test result often indicates that VIR-7831 sotrovimab will be effective. VIR-7831 sotrovimab is also used when a patient is at high risk for severe covid-19, is overweight, or has mild to moderate covid-19 symptoms."
Are there any other existing papers on VIR-7831 sotrovimab?
"There are 266 clinical trial sites for VIR-7831 sotrovimab located around the world, with 4 active trials and 2 of those in Phase 3."
Are there any dangerous side-effects to sotrovimab treatment?
"There is existing clinical data that supports the efficacy of VIR-7831 sotrovimab, making it a 3 on our safety scale."
Are there any inclusion or enrollment criteria for this experiment?
"This particular trial has completed recruitment for patients. The trial was first announced on June 10th, 2021 and was most recently updated on July 21st, 2022. There are presently 1137 studies actively recruiting participants with covid-19 and 4 trials for VIR-7831 sotrovimab actively recruiting participants."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger